Comparative Pharmacology
Head-to-head clinical analysis: LOPRESSOR HCT versus TRIVARIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOPRESSOR HCT versus TRIVARIS.
LOPRESSOR HCT vs TRIVARIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LOPRESSOR HCT is a combination of metoprolol tartrate (a beta-1 selective adrenergic receptor blocker) and hydrochlorothiazide (a thiazide diuretic). Metoprolol reduces heart rate, myocardial contractility, and blood pressure by blocking beta-1 receptors in the heart. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing plasma volume.
TRIVARIS combines an opioid agonist-antagonist (buprenorphine) and a mu-opioid receptor antagonist (naloxone). Buprenorphine partially binds to mu-opioid receptors, reducing withdrawal and craving, while naloxone precipitates withdrawal if injected, deterring abuse.
1-2 tablets (each containing metoprolol tartrate 50 mg and hydrochlorothiazide 25 mg) orally once daily, maximum 4 tablets daily.
TRIVARIS 10 mg orally once daily, with or without food.
None Documented
None Documented
Metoprolol: 3-7 hours (terminal half-life); extensive metabolizers (CYP2D6) ~3-4 h, poor metabolizers ~7-8 h. Hydrochlorothiazide: 6-15 hours (terminal half-life).
Terminal half-life 12-18 hours; allows twice-daily dosing in chronic therapy
Metoprolol: <5% unchanged in urine; rest metabolized in liver (CYP2D6) and excreted renally as metabolites. Hydrochlorothiazide: >95% excreted unchanged in urine within 24 hours via tubular secretion.
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% minor pathways
Category C
Category C
Beta-Blocker/Thiazide Diuretic Combination
Angiotensin II Receptor Blocker + Calcium Channel Blocker + Thiazide Diuretic Combination